Polaris Group announced today that the first patient has been dosed in a phase 1B trial of ADI‑PEG 20 in combination with Radiotherapy and Temozolomide for the treatment of Newly Diagnosed Glioblastoma Multiforme (GBM). The Lead Investigator is Dr. Wei from Linkou Chang Gung Memorial Hospital. There will be 26 patients enrolled in this phase 1B trial.

This month, Tmunity Therapeutics is dosing the first patients who have enrolled in an early clinical trial testing an engineered CAR-T immune cell therapy for metastatic prostate cancer. The trial's start is notable, and not just because it's been challenging to recruit patients for cancer trials during the COVID-19 pandemic. The experimental CAR-T is among the first cell therapies to target a solid tumor—an enemy that was once considered too difficult to tackle with that type of treatment.

 [Taipei, Taiwan] – After completion of its first and second licensing agreement milestones for its breast cancer biosimilar, EG12014 (Trastuzumab Biosimilar, also called EGI014), EirGenix, Inc. (6589.TT) has completed its third licensing agreement milestone today.

Acepodia, a biotechnology company developing next generation solid tumor and blood-based cancer cell therapies, today announced key appointments to its business and clinical development teams. Mark J. Gilbert, M.D., a cell therapy pioneer, joins as senior vice president of Research and Development and will lead early-stage research efforts to advance the company’s proprietary, potent and off-the-shelf cell therapies from exploratory development stages into clinical trials. Joseph S. McCracken, D.V.M., an industry veteran with over 25 years of experience in the biopharmaceutical industry, has been appointed as senior vice president of Business Development and will play a key role in driving strategic alliances and partnerships.

LEIDEN, Netherlands and OSS, Netherlands and PISCATAWAY, New Jersey, Sept. 15, 2020 /PRNewswire/ -- Innatoss Laboratories announced today the first neutralizing antibody testing service against SARS-CoV-2 for the public in Europe, using GenScript's cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit.

ESR1 mutations have been reported that will contribute to the resistance of the aromatase inhibitor (AI) in HR+ breast cancer patients in several past studies. However, the role of ESR1 mutation remains unknown when the AI is combined with the CDK4/6 inhibitors. In phase 3 PADA-1 study, 33 of the 1017 enrolled patients (3.2%) harbored an ESR1 mutation before receiving the 1st-line AI plus palbociclib.

On August 27th, Taiwan FDA announced its approval of Vstrip® COVID-19 Antigen Rapid Test under Emergency Use Authorization (EUA).

Brain tumors are rare but difficult to manage. Glioma is the most common type of tumor in the brain that begins in glial cells. IDH1/2 genes are important genes in both glioma classification and targeted therapy treatment. Adult diffuse gliomas of grade II and III are classified as low-grade gliomas based on the histology and molecular biomarkers by the 2016 World Health Organization (WHO) classification.

•   ACE1702 is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors

•   Clinical trial expected to enroll up to 24 patients across the U.S.

* ARTHROSI THERAPEUTICS INC SAYS HAS RAISED $8.5 MILLION IN EQUITY FINANCING FROM TOTAL OFFERING AMOUNT OF $20 MILLION - SEC FILING